Genotoxic therapies were independent prognostic factors in IDH mutated grade II and grade III gliomas but lost significance in IDH mutated subgroups divided by the status of 1p/19q codeletion and TERT promoter mutations. The gene discussed is TERT; the disease is central nervous system cancer.